A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
| Condition | Intervention | Phase |
|---|---|---|
|
Detrusor Hyperreflexia |
Drug: Oxybutynin transdermal system |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury |
- Average Number of Catheterizations Without Leaking Per Day [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Baseline in number of daily catheterizations without leaking per day as recorded in a 3-day urinary diary.
- Patch Adhesion [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- Urodynamic Measurements [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- Urinary Leakage and Catheterization Data [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 24 |
| Study Start Date: | December 2004 |
| Study Completion Date: | May 2008 |
| Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Oxybutynin transdermal system
Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing
|
Drug: Oxybutynin transdermal system
3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
Other Name: Oxytrol
|
Detailed Description:
The Dose Titration Period began with a 3.9 mg/day or 7.8 mg/day as a starting dose after the completion of a 3-day diary for baseline evaluations, including urodynamic testing. The clean intermittent catheterization (CIC) frequency remained constant throughout the Dose Titration Period. The dose was adjusted every two weeks during the Dose Titration Period by increasing one dose level, at the investigator's discretion, based on the patient's symptoms. If a patient achieved complete continence and reported tolerable or absence of side effects, the patient was continued at that dose for the duration of the 8-week Titration Period. If a patient reported unacceptable side effects, the dose was reduced by one level. This reduced dose was considered the maximum tolerable dose for the patient and the patient continued at that dose for the duration of the 8-week Titration Period. The dose levels evaluated were 3.9 mg/day, 7.8 mg/day, 9.1 mg/day, and 11.7 mg/day. Of the 22 subjects in the modified intent-to-treat population evaluated for efficacy, 0 were in the 3.9 mg/day dose group, 3 were in the 7.8 mg/day dose group, 8 were in the 9.1 mg/day dose group, and 11 were in the 11.7 mg/day dose group.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- At least 18 years of age at day of consent;
- Is a male, or is a non-pregnant non-lactating female who is either of non-child-bearing potential, or is using adequate means of birth control;
- Has a h/o of urinary incontinence from neurogenic bladder of spinal cord injury etiology;
- Has impairment based on the American Spinal Injury Association (ASIA);
- Use clean intermittent catheterization;
- Has urinary incontinence between scheduled catheterization;
- Capable of understanding and complying with the protocol.
Exclusion Criteria:
- Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency;
- Have any medical condition that precludes their participation in the study, or may confound the outcome of the study;
- History of major lower urinary tract surgery, procedures;
- Has an active skin disorder, affecting TDS application site areas;
- Hypersensitivity to the investigational drug;
- Has participated in any study involving administration of an investigational compound within 30 days before this study.
Contacts and Locations| United States, Georgia | |
| Atlanta, Georgia, United States | |
| United States, New York | |
| Bronx, New York, United States | |
| United States, North Carolina | |
| Chapel Hill, North Carolina, United States | |
| Charlotte, North Carolina, United States | |
| United States, Texas | |
| Dallas, Texas, United States | |
| Houston, Texas, United States | |
| Study Director: | Gary Hoel, RPh, PhD | Watson Laboratories, Inc. |
More Information
Publications:
| Responsible Party: | Gary Hoel, RPh, PhD, Watson Laboratories, Inc |
| ClinicalTrials.gov Identifier: | NCT00224029 History of Changes |
| Other Study ID Numbers: | OXY0401 |
| Study First Received: | September 13, 2005 |
| Results First Received: | November 13, 2009 |
| Last Updated: | April 7, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Spinal Cord Injuries Reflex, Abnormal Urinary Bladder, Overactive Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Wounds and Injuries Neurologic Manifestations Signs and Symptoms Urinary Bladder Diseases Urologic Diseases |
Urological Manifestations Oxybutynin Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013